SMARCD3 and neoplasm: While embryonic Smarcd3 deletion concomitant with RAS activation slightly promoted the emergence of benign cystic lesions arising from pancreatic progenitors (Supplementary Fig. 2a), Smarcd3 deletion in adulthood with RAS activation did not significantly impact the development of early PanIN lesions arising from pancreatic cells of either lineage, indicating that Smarcd3 does not play a key role in early tumor initiation (Supplementary Fig. 2a–c).